Oxford Biomedica PLC — Regulatory Filings 2018

Nov 9, 2018

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 8500G

Oxford Biomedica PLC

09 November 2018

Oxford BioMedica

Block listing Application

Oxford, UK - 09 November 2018: Oxford BioMedica plc ("OXB" or "the Group") (LSE: OXB), a leading gene and cell therapy group, announces that applications have been made to the Financial Conduct Authority and the London Stock Exchange for admission to (i) the Premium segment of the Official List and (ii) to trading on the London Stock Exchange for a block listing of 300,000 ordinary shares of 50 pence each (the "Ordinary Shares").

The Ordinary Shares are being reserved under a block listing and will be issued from time to time pursuant to the following scheme:

·      Save As You Earn (SAYE) Option Scheme.

It is expected that admission of the Ordinary Shares will become effective on 12 November 2018. The Ordinary Shares will rank pari passu in all respects with the Group's existing ordinary shares in issue.

-Ends-

For further information, please contact:
Oxford BioMedica plc: Stuart Paynter, Company Secretary	Tel: +44 (0)1865 783 000

Notes to editors

Oxford BioMedica (LSE:OXB) is a leading gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford BioMedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector®), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders. The Group has also entered into a number of partnerships, including with Novartis, Bioverativ, Sanofi, Axovant, Orchard Therapeutics, Boehringer Ingelheim/UK Cystic Fibrosis Gene Therapy Consortium/Imperial Innovations, GC LabCell and Immune Design, through which it has long-term economic interests in other potential gene and cell therapy products. Oxford BioMedica is based across several locations in Oxfordshire, UK and employs more than 360 people. Further information is available at www.oxfordbiomedica.co.uk.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

ALSDXBDBIXGBGII